WO1999056772A2 - Hepatitis vaccine - Google Patents

Hepatitis vaccine Download PDF

Info

Publication number
WO1999056772A2
WO1999056772A2 PCT/EP1999/003024 EP9903024W WO9956772A2 WO 1999056772 A2 WO1999056772 A2 WO 1999056772A2 EP 9903024 W EP9903024 W EP 9903024W WO 9956772 A2 WO9956772 A2 WO 9956772A2
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine composition
hepatitis
formol
dose
aluminium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/003024
Other languages
English (en)
French (fr)
Other versions
WO1999056772A3 (en
Inventor
Claude Artois
Michael J. Clark
Clothilde Thiriart
Stefan Gabriel Jozef Thoelen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69934108T priority Critical patent/DE69934108T2/de
Priority to JP2000546796A priority patent/JP5138843B2/ja
Priority to EP99924871A priority patent/EP1073462B1/en
Priority to IL13926999A priority patent/IL139269A0/xx
Priority to CA2331086A priority patent/CA2331086C/en
Priority to HU0101652A priority patent/HU228209B1/hu
Priority to AU41379/99A priority patent/AU743759B2/en
Priority to PL99344137A priority patent/PL190729B1/pl
Priority to BR9910157-2A priority patent/BR9910157A/pt
Priority to NZ507902A priority patent/NZ507902A/en
Priority to DK99924871T priority patent/DK1073462T3/da
Priority to SI9930935T priority patent/SI1073462T1/sl
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to HK01104910.8A priority patent/HK1034202B/en
Publication of WO1999056772A2 publication Critical patent/WO1999056772A2/en
Publication of WO1999056772A3 publication Critical patent/WO1999056772A3/en
Priority to NO20005483A priority patent/NO20005483L/no
Anticipated expiration legal-status Critical
Priority to US10/883,126 priority patent/US7144703B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Vaccines for the prophylaxis of hepatitis A and hepatitis B infections are well known.
  • the vaccine Engerix-B (Trade Mark) from SmithKline Beecham Biologicals is used to prevent Hepatitis B.
  • This vaccine comprises hepatitis B surface antigen (specifically the 226 amino acid S- antigen described in Harford et al. in Postgraduate Medical Journal, 1987, 63 (Suppl. 2), 65-70) and is formulated using aluminium hydroxide as adjuvant.
  • the vaccine Havrix also from SmithKline Beecham Biologicals can be used to prevent hepatitis A infections and is also formulated with aluminium hydroxide as adjuvant.
  • This vaccine comprises an attenuated strain of the HM-175 Hepatitis A virus inactivated with formol (formaldehyde); see Andre et al [Prog Med. Virol. 1990, vol 37; p72-95].
  • the vaccine Twinrix (Trade Mark) which is a combination of the above hepatitis A and hepatitis B antigens may be used to protect against hepatitis A and hepatitis B simultaneously.
  • European patent 0 339 667 (Chemo Sero) describes the general concept of combining a hepatitis A antigen and a hepatitis B antigen to make a combination vaccine.
  • the adjuvant which is used is not critical: it must only be capable of enhancing the immune activity to a desired extent and not cause any side- effects.
  • aluminium gel may be used, in particular aluminium hydroxide gel and aluminium phosphate gel.
  • PCT application WO 93/24148 (SmithKline Beecham) describes the preparation of vaccines comprising hepatitis B surface antigen in which aluminium phosphate is used as adjuvant. Multivalent combination vaccines which may optionally contain a hepatitis A antigen, are described. The use of formol is not disclosed.
  • European Patent Number 0 633 784 (SmithKline Beecham) describes novel vaccine formulations comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminium phosphate, and 3 de-O-acylated monophosphoryl lipid A. It has now been surprisingly found that vaccines comprising hepatitis B and/or hepatitis A antigens give exceptionally good results if the vaccine is formulated in a specific manner.
  • vaccine formulations according to the invention it is possible to administer the vaccines in a 2 dose, rather than a 3 dose, regimen.
  • an aqueous vaccine composition comprising hepatitis B surface antigen which is formulated with aluminium phosphate as adjuvant, the concentration of aluminium phosphate being selected such that there is a ratio of 0.015-0.1 mg aluminium phosphate per ug hepatitis B surface antigen.
  • the ratio is in the range 0.02 to 0.08mg aluminium phosphate per ⁇ g HBsAg.
  • an inactivated hepatitis A virus may optionally be added to the formulation of the invention, providing a combined hepatitis A plus B vaccine which may be administered in a 2 dose schedule.
  • HAV hepatitis A virus
  • the hepatitis A antigen is preferably the HM-175 strain used in the commercial product Havrix (SmithKline Beecham Biologicals).
  • the concentration of hepatitis A antigen in the vaccine formulation of the invention is preferably about 720-2880 EU units per ml.
  • EU units see Andre et al (1990) loc cit.
  • compositions of the invention which comprise HAV may additionally comprise aluminium hydroxide, the total amount of aluminium hydroxide generally being 0.05- 0.10 mg per ml.
  • the total amount of aluminium salt per 0.5 or 1 ml dose is normally in the range 0.4- l .Omg.
  • formol formaldehyde
  • the formol concentration is about 20-160 ⁇ g per ml.
  • hepatitis B antigen will be hepatitis B surface antigen (HBsAg).
  • HBsAg hepatitis B surface antigen
  • the preparation of Hepatitis B surface antigen (HBsAg) is well documented. See for example, Harford et al in Develop. Biol. Standard 54, page 125 (1983), Gregg et al in Biotechnology, 5, page 479 (1987), EP-A- 0 226 846, EP-A-0 299 108 and references therein.
  • Hepatitis B surface antigen' or 'HBsAg' includes any HBsAg antigen or fragment thereof displaying the antigenicity of HBV surface antigen. It will be understood that in addition to the 226 amino acid sequence of the HBsAg S antigen (see Tiollais et al, Nature, 317, 489 (1985) and references therein) HBsAg as herein described may, if desired, contain all or part of a pre-S sequence as described in the above references and in EP-A- 0 278 940. HBsAg as herein described can also refer to variants, for example the 'escape mutant' described in WO 91/14703.
  • the HBsAg may comprise a pro tein described as SL* in European Patent Application Number 0 414 374, that is to say a protein, the amino acid sequence of which consists of parts of the amino acid sequence of the hepatitis B virus large (L) protein (ad or ay subtype), characterised in that the amino acid sequence of the protein consists of either:
  • HBsAg may also refer to polypeptides described in EP 0 198 474 or EP 0 304 578. Normally the HBsAg will be in particle form. It may comprise S protein alone or may be as composite particles, for example (L*,S) wherein L* is as defined above and S denotes the S-protein of hepatitis B surface antigen.
  • the HBsAg will be adsorbed on aluminium phosphate as described in WO93/24148.
  • the hepatitis B antigen is HBsAg S-antigen as used in the commercial product Engerix-B (SmithKline Beecham Biologicals).
  • the vaccine formulations of the present invention will contain an immunoprotective quantity of the antigens and may be prepared by conventional techniques.
  • Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978.
  • Encapsulation within liposomes is described, for example, by Fullerton, U.S. Patent 4,235,877.
  • Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, U.S. Patent 4,372,945 and by Armor et al., U.S. Patent 4,474,757.
  • the vaccine compositions of the invention are preferably administered in a 0, 6 month schedule, that is to say a first dose at 0 months and a second dose at 6 months.
  • the vaccine compositions of the present invention are especially appropriate for adults and are also appropriate for administration to adolescents and children.
  • a vaccine composition for administration to adults which comprises: 40 ⁇ g HBsAg
  • Aluminium salt (0.8mg aluminium phosphate plus 0.05mg aluminium hydroxide)
  • a vaccine composition for administration to adults which comprises: 40 ⁇ g HBsAg
  • Aluminium salt (0.8mg aluminium phosphate plus 0.05mg aluminium hydroxide)
  • a vaccine composition for administration to adolescents and/or children which comprises:
  • Aluminium salt (0.4mg aluminium phosphate plus 0.05mg aluminium hydroxide)
  • a vaccine composition for administration to adolescents and/or children which comprises:
  • Aluminium salt (0.4mg aluminium phosphate plus 0.05mg aluminium hydroxide)
  • the immunization schedule for HAB 054 was 0,6 (i.e. doses administered at month 0 and month 6).
  • the Hepatitis B serological results at months 2,6 and 7 were unexpectedly high as compared to historical results obtained in another study (HBV NF 021) in which volunteers of the same age group were included.
  • Study HBV NF 021 included three groups :
  • Group 1 Vaccinated with a formulation containing 40 ⁇ g of HBsAg on 0.5 ⁇ g AlPO 4 in 0.5ml volume without formol, schedule 0, 6 months (this is abbreviated in the table to NF 40 ⁇ g, 0, 6M)
  • Group 2 Vaccinated with a formulation containing 20 ⁇ g of HBsAg on 0.5 ⁇ g AlPO 4 in 0.5ml volume without formol, schedule 0, 6 months (this is abbreviated in the table to NF 20 ⁇ g, 0, 6M)
  • Group 3 Vaccinated with an Engerix B formulation (20 ⁇ g) using a classical 3 dose immunization schedule of 0, 1, 6 months (third row of data in Table 1 )
  • HAV 1440/NF40 contains 0.85mg Al salts - 0.8 Al P0 4 20 ⁇ g formol in 1ml
  • Vaccine composition comprises: 720 HAV EU / 20 ⁇ g HBs Ag 0.25mg Al Salt 40 ⁇ g formol
  • Vaccine composition group 1 Two groups were used in this study. Vaccine composition group 1 :
  • Vaccine composition group 2 (Twinrix TM Junior):
  • Vaccine composition group 1 (Twinrix TM ). 720 HAV EU / 20 ⁇ g HBs Ag 0.45mg Al Salt 80 ⁇ g formol
  • Vaccine composition group 2 1440 HAV EU / 40 ⁇ g HBs Ag
  • Vaccine composition group 1 (Twinrix TM ).
  • Vaccine composition group 2 (Twinrix TM Junior): 360 HAV EU / 10 ⁇ g HBs Ag 0.225mg Al Salt 40 ⁇ g formol
  • Vaccine composition comprises: 720 HAV EU / 20 ⁇ g HBs Ag 0.45mg Al Salt 80 ⁇ g formol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/EP1999/003024 1998-05-01 1999-04-27 Hepatitis vaccine Ceased WO1999056772A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2000546796A JP5138843B2 (ja) 1998-05-01 1999-04-27 新規組成物
EP99924871A EP1073462B1 (en) 1998-05-01 1999-04-27 Combined vaccine against Hepatitis A and Hepatitis B
IL13926999A IL139269A0 (en) 1998-05-01 1999-04-27 Hepatitis vaccine
CA2331086A CA2331086C (en) 1998-05-01 1999-04-27 Hepatitis vaccine
HU0101652A HU228209B1 (en) 1998-05-01 1999-04-27 New composition
AU41379/99A AU743759B2 (en) 1998-05-01 1999-04-27 Novel composition
PL99344137A PL190729B1 (pl) 1998-05-01 1999-04-27 Nowa kompozycja
NZ507902A NZ507902A (en) 1998-05-01 1999-04-27 Novel hepatitis vaccine composition
BR9910157-2A BR9910157A (pt) 1998-05-01 1999-04-27 Composição
DE69934108T DE69934108T2 (de) 1998-05-01 1999-04-27 Kombinierte Impfstoffe gegen Hepatitis A und Hepatitis B
SI9930935T SI1073462T1 (sl) 1998-05-01 1999-04-27 Kombinirano cepivo proti hepatitisu A in hepatitisu B
DK99924871T DK1073462T3 (da) 1998-05-01 1999-04-27 Kombinationsvaccine mod hepatitis A og hepatitis B
HK01104910.8A HK1034202B (en) 1998-05-01 1999-04-27 Combined vaccine against hepatitis a and hepatitis b
NO20005483A NO20005483L (no) 1998-05-01 2000-10-31 Ny sammensetning
US10/883,126 US7144703B2 (en) 1998-05-01 2004-07-01 Composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9809507.8 1998-05-01
GBGB9809507.8A GB9809507D0 (en) 1998-05-01 1998-05-01 Novel composition

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09674397 A-371-Of-International 2000-10-31
US10/223,801 Continuation US20030049268A1 (en) 1998-05-01 2002-08-20 Novel composition

Publications (2)

Publication Number Publication Date
WO1999056772A2 true WO1999056772A2 (en) 1999-11-11
WO1999056772A3 WO1999056772A3 (en) 2000-02-03

Family

ID=10831426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003024 Ceased WO1999056772A2 (en) 1998-05-01 1999-04-27 Hepatitis vaccine

Country Status (28)

Country Link
EP (1) EP1073462B1 (enExample)
JP (2) JP5138843B2 (enExample)
KR (1) KR100612547B1 (enExample)
CN (1) CN1263509C (enExample)
AR (1) AR016987A1 (enExample)
AT (1) ATE345815T1 (enExample)
AU (1) AU743759B2 (enExample)
BR (1) BR9910157A (enExample)
CA (1) CA2331086C (enExample)
CO (1) CO5050367A1 (enExample)
CY (1) CY1107322T1 (enExample)
CZ (1) CZ301232B6 (enExample)
DE (1) DE69934108T2 (enExample)
DK (1) DK1073462T3 (enExample)
ES (1) ES2277437T3 (enExample)
GB (1) GB9809507D0 (enExample)
GC (1) GC0000101A (enExample)
HU (1) HU228209B1 (enExample)
IL (1) IL139269A0 (enExample)
MY (1) MY128929A (enExample)
NO (1) NO20005483L (enExample)
NZ (1) NZ507902A (enExample)
PL (1) PL190729B1 (enExample)
PT (1) PT1073462E (enExample)
TR (1) TR200003235T2 (enExample)
TW (1) TW553744B (enExample)
WO (1) WO1999056772A2 (enExample)
ZA (1) ZA200006118B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
CN102988975A (zh) * 2012-11-30 2013-03-27 深圳康泰生物制品股份有限公司 甲型、乙型肝炎联合疫苗及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1513555A (zh) * 2003-07-31 2004-07-21 长春生物制品研究所 甲-乙型肝炎联合疫苗及其冻干制剂
CN102198270B (zh) * 2011-05-16 2012-06-27 大连汉信生物制药有限公司 一种含铝佐剂乙肝疫苗的制备方法
KR101281098B1 (ko) * 2011-06-30 2013-07-02 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
IL283039B2 (en) * 2018-11-13 2025-01-01 Variation Biotechnologies Inc Immunological preparations for the treatment of hepatitis B

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0349686A (ja) * 1989-07-11 1991-03-04 Smithkline Biologicals Sa レトロウイルスｇａｇ蛋白の真核生物細胞における発現
DE122010000016I1 (de) * 1992-05-23 2010-07-08 Glaxosmithkline Biolog Sa Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
DE69731357T2 (de) * 1996-03-23 2006-02-02 The Research Foundation For Microbial Diseases Of Osaka University, Suita Funktionelles antigenfragment von tetanustoxin und tetanusvakzine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
WO2007137847A1 (en) * 2006-05-31 2007-12-06 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Process for production of a vaccine composition
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
WO2007137846A1 (en) * 2006-06-01 2007-12-06 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Process for production of a vaccine composition
CN102988975A (zh) * 2012-11-30 2013-03-27 深圳康泰生物制品股份有限公司 甲型、乙型肝炎联合疫苗及其制备方法

Also Published As

Publication number Publication date
AR016987A1 (es) 2001-08-01
CN1308547A (zh) 2001-08-15
HUP0101652A3 (en) 2004-10-28
KR20010043224A (ko) 2001-05-25
CZ20004061A3 (cs) 2001-04-11
PL190729B1 (pl) 2005-12-30
CO5050367A1 (es) 2001-06-27
DE69934108T2 (de) 2007-04-19
MY128929A (en) 2007-02-28
AU4137999A (en) 1999-11-23
CZ301232B6 (cs) 2009-12-16
JP5138843B2 (ja) 2013-02-06
NZ507902A (en) 2002-03-28
ZA200006118B (en) 2002-01-30
HU228209B1 (en) 2013-01-28
IL139269A0 (en) 2001-11-25
TR200003235T2 (tr) 2001-03-21
KR100612547B1 (ko) 2006-08-11
BR9910157A (pt) 2001-01-09
ES2277437T3 (es) 2007-07-01
ATE345815T1 (de) 2006-12-15
CN1263509C (zh) 2006-07-12
GB9809507D0 (en) 1998-07-01
NO20005483D0 (no) 2000-10-31
EP1073462A2 (en) 2001-02-07
NO20005483L (no) 2000-12-08
DK1073462T3 (da) 2007-02-26
CY1107322T1 (el) 2012-11-21
CA2331086A1 (en) 1999-11-11
PL344137A1 (en) 2001-10-08
GC0000101A (en) 2005-06-29
WO1999056772A3 (en) 2000-02-03
TW553744B (en) 2003-09-21
AU743759B2 (en) 2002-02-07
DE69934108D1 (de) 2007-01-04
PT1073462E (pt) 2007-01-31
JP2002513771A (ja) 2002-05-14
HUP0101652A1 (hu) 2001-09-28
EP1073462B1 (en) 2006-11-22
HK1034202A1 (en) 2001-10-19
JP2010209118A (ja) 2010-09-24
CA2331086C (en) 2010-06-22

Similar Documents

Publication Publication Date Title
AP766A (en) A vaccine based on hepatitis B antigen.
US6013264A (en) Vaccine
WO1993019780A1 (en) Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a
JP2010209118A (ja) 新規組成物
JP2001503422A (ja) ジフテリア―及び破傷風毒素による無細胞百日咳ワクチン
US7144703B2 (en) Composition
US6488934B1 (en) Hepatitis B vaccine
HK1034202B (en) Combined vaccine against hepatitis a and hepatitis b
HK1004117B (en) Hepatitis b vaccine
HK1147950A (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
HK1021142B (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
HK1137937A (en) Combined vaccines comprising hepatitis b surface antigen and other antigens

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808141.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 41379/99

Country of ref document: AU

Ref document number: 139269

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2331086

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000/06118

Country of ref document: ZA

Ref document number: 200006118

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 09674397

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 507902

Country of ref document: NZ

Ref document number: 1020007012162

Country of ref document: KR

Ref document number: PA/a/2000/010796

Country of ref document: MX

Ref document number: PV2000-4061

Country of ref document: CZ

Ref document number: 2000/03235

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/595/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1999924871

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999924871

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-4061

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007012162

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 41379/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007012162

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1020007012162

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1999924871

Country of ref document: EP